相关实验视频

Updated: Jun 11, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

向CD276用于T细胞基免疫治疗乳腺癌

Ilona Hagelstein^1,2, Laura Wessling¹, Alexander Rochwarger³

¹Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, German Cancer Consortium (DKTK), University Hospital Tübingen, Otfried-Müller-Str. 10, 72076, Tübingen, Germany.

Journal of translational medicine

|October 4, 2024

概括

一种针对CD276 (B7-H3) 的新型双特异性抗体CC-3显示为乳腺癌 (BC) 免疫疗法的前景. 这种疗法有效地激活T细胞和溶解瘤细胞,为患者提供了新的治疗途径,特别是那些患有三阴性BC的患者.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
癌症生物学癌症生物学

背景情况:

乳腺癌 (BC) 是女性的主要恶性瘤.
虽然免疫疗法已经推进了BC治疗,但许多患者仍然不合格或没有反应.
三重阴性乳腺癌 (TNBC) 对新型疗法有着显著的未满足的医疗需求.

研究的目的:

研究CD276 (B7-H3) 作为乳腺癌中潜在的免疫治疗点.
在BC的临床前模型中评估新型双特异抗体CC-3 (CD276xCD3) 的治疗疗效.

主要方法:

用免疫组织化学分析了25名患者瘤样本中的CD276表达.
在体外功能测试中评估了CC-3对BC细胞和T细胞的活性.

主要成果:

在所有分析的BC样本中,CD276的表达高,包括三阴性亚型.
CC-3证明了强大的T细胞激活,增殖和记忆子集形成.
用CC-3治疗导致显著的细胞因子分泌和直接的瘤细胞溶解.

结论:

CD276是乳腺癌的一个有前途的治疗点.
双特异性抗体CC-3表现出显著的临床前抗瘤活性.
这些发现支持在BC患者中对CC-3的临床评估,现在已经开始进行临床试验.

关键词:

B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 B7-H3 双特异性抗体双特异性抗体乳腺癌乳腺癌乳腺癌 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD276 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD4 CD3 CD4 CD4 CD4 CD4 CD5 CD5 CD5 CD5 CD5 CD6 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD8 CD8 CD8 CD8 CD8 CD8 CD9 免疫治疗是一种免疫疗法.一个T细胞细胞.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...